H3K14ac is linked to methylation of H3K9 by the triple Tudor domain of SETDB1 by Jurkowska, Renata Z. et al.
ARTICLE
H3K14ac is linked to methylation of H3K9 by the
triple Tudor domain of SETDB1
Renata Z. Jurkowska 1, Su Qin2,3, Goran Kungulovski1, Wolfram Tempel2, Yanli Liu2, Pavel Bashtrykov1,
Judith Stiefelmaier1, Tomasz P. Jurkowski 1, Srikanth Kudithipudi1, Sara Weirich1, Raluca Tamas1, Hong Wu2,
Ludmila Dombrovski2, Peter Loppnau2, Richard Reinhardt4, Jinrong Min2,5 & Albert Jeltsch 1
SETDB1 is an essential H3K9 methyltransferase involved in silencing of retroviruses and gene
regulation. We show here that its triple Tudor domain (3TD) speciﬁcally binds to doubly
modiﬁed histone H3 containing K14 acetylation and K9 methylation. Crystal structures of
3TD in complex with H3K14ac/K9me peptides reveal that peptide binding and K14ac
recognition occurs at the interface between Tudor domains (TD) TD2 and TD3. Structural
and biochemical data demonstrate a pocket switch mechanism in histone code reading,
because K9me1 or K9me2 is preferentially recognized by the aromatic cage of TD3, while
K9me3 selectively binds to TD2. Mutations in the K14ac/K9me binding sites change the sub-
nuclear localization of 3TD. ChIP-seq analyses show that SETDB1 is enriched at H3K9me3
regions and K9me3/K14ac is enriched at SETDB1 binding sites overlapping with LINE ele-
ments, suggesting that recruitment of the SETDB1 complex to K14ac/K9me regions has a role
in silencing of active genomic regions.
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H istone posttranslational modiﬁcations (PTMs) are essen-tial for the regulation of chromatin states1,2. Trimethy-lation of histone H3 at lysine 9 (H3K9me3) is a hallmark
of facultative and constitutive heterochromatin in almost all
eukaryotes3–6, and it is also enriched in silenced genes7. In con-
trast, monomethylated H3K9 is found in the promoter regions of
active genes7 and histone acetylation is a signal of active tran-
scription and open chromatin8. SETDB1 (also known as ESET or
KMT1E) is a histone H3K9 methyltransferase that generates
H3K9me3 in euchromatic regions9. Gene knockout studies have
shown that it is essential for early development in mice10.
SETDB1 plays a critical role in gene regulation11, and it forms a
complex with KAP-1 (also called TRIM28) that is required in
embryonic stem cells12,13, primordial germ cells14, and B lym-
phocytes15. SETDB1 is also recruited to target sites by the HUSH
complex16 and it associates with additional silencing factors
including DNMT3A17, other H3K9 PKMTs18, and the NuRD
HDAC chromatin remodeling complex19–21. The KAP-1/
SETDB1 complex is required for silencing of LTR
retroviruses12–15, and it has also been connected to H3K9
methylation of LINE elements14,15,22–24.
Histone-modifying enzymes often contain small functional
domains for readout of speciﬁc histone PTMs that are involved in
their recruitment and regulation of their enzymatic activity25.
SETDB1 contains three Tudor domains (3TD) and a methyl-CpG
binding domain (MBD) in its N-terminal part, followed by a split
SET domain, which harbors the catalytic center for H3K9
methylation (Fig. 1a). Tudor domains are known to recognize
methylated lysine and arginine26,27, but the potential binding
ligand of the SETDB1 Tudor domains and their role in SETDB1
function remains unclear. We show here that SETDB1 3TD binds
to histone H3 tails containing K14 acetylation combined with K9
methylation. Crystal structures revealed that K14ac recognition
occurs at the interface between Tudor domain 2 (TD2) and
Tudor domain 3 (TD3). Depending on the methylation state of
K9, the methyllysine is preferentially bound by the aromatic cage
of TD3 (K9me1 and K9me2) or TD2 (K9me3). Ectopic expres-
sion of 3TD wildtype and mutants fused to ﬂuorophores
demonstrates that the intact K14ac/K9me binding sites have an
important role in the sub-nuclear localization of 3TD. We show
that K9me3/K14ac regions bound by SETDB1 are enriched in
LINE elements and propose that 3TD-mediated recruitment of
SETDB1 to chromatin-containing active marks (K14ac) con-
tributes to the efﬁcient silencing of these regions. In summary, we
characterize a reader for the combined K14ac/K9me mark,
demonstrate the role of Tudor domains in binding acetyllysine,
and identify a pocket switch mechanism in histone reading
domains. Future work will show if this modiﬁcation-dependent
conformational change of the substrate triggers any downstream
effects in SETDB1 or any of its complex partners.
Results
3TD binds H3 peptides containing K9me1/2/3 and K14ac. To
study the function of the triple Tudor domain (3TD) of SETDB1,
we ﬁrst investigated the histone peptide binding ability of the
GST-tagged 3TD. Using modiﬁed histone peptide arrays, we
identiﬁed strong and selective binding of 3TD to three combi-
natorially modiﬁed H3 peptides: H3K9me1/K14ac, H3K9me2/
K14ac, and H3K9me3/K14ac (Fig. 1b). Peptide array binding
experiments at 100-fold increased concentration of 3TD detected
weaker binding to monomodiﬁed H3K14ac, but no binding to
H3K9me (Supplementary Fig. 1a). To further evaluate the relative
contribution of each modiﬁcation to the overall binding, we
performed Isothermal Titration Calorimetry (ITC) and NMR
chemical shift perturbation binding experiments with different
peptides, which conﬁrmed the binding and revealed dissociation
constants (Kd) in the lower micromolar range for H3K9me/K14ac
peptides (Fig. 2a, b). In agreement with the peptide array binding
results, these experiments revealed that although the acetylation
at H3K14 is indispensable for 3TD binding, binding to mono-
modiﬁed H3K14ac was very weak. Methylation of H3K9 alone
was insufﬁcient for binding, but it strongly enhanced binding
when combined with K14ac (Fig. 2b, c, Supplementary Fig. 1b, c).
Peptide SPOT array binding experiments conﬁrmed the
requirement of K9me/K14ac for 3TD binding (Fig. 1d). In
addition, binding of 3TD to an alanine scanning peptide SPOT
array showed that the H3 sequence between T11 and P16 is
critical for the interaction (Fig. 1e). The binding of the Tudor
domains of SETDB1 to methylated histone tails has been inves-
tigated previously, but no binding was observed28. This could be
explained by the fact that the speciﬁc K9me/K14ac combination
of modiﬁcations was not tested in that study. Taken together, we
conclude that the 3TD domain of SETDB1 speciﬁcally recognizes
the acetylation mark of H3K14 and methylation of H3K9 on the
same histone tail strongly enhances the binding afﬁnity.
Mode of histone H3 binding by the 3TD domain of SETDB1.
To understand the molecular basis for the recognition of the
combinatorial H3K9me/K14ac histone mark, we solved the
crystal structure of 3TD in complex with an H3(4–19) K9me2/
K14ac doubly modiﬁed peptide (Fig. 3, Supplementary Figs. 2 and
3, Supplementary Table 1). The three Tudor domains compose a
stack, in which the individual domains interact with each other
face-to-back. Each domain forms a β-barrel-like fold character-
istic of Tudor domains26, with the barrel bottoms pointing in the
same direction. Notably, there are extensive interactions among
the Tudor domains and the inter-domain linkers, indicating that
3TD folds and functions as a single unit (Supplementary Fig. 2a).
The histone H3 peptide lies in a groove formed by TD2, TD3, and
the linker between them (Fig. 3a, b). The speciﬁcity of the H3
peptide interaction is determined mainly through (1) recognition
of K14ac by an acetyl-lysine binding groove between TD2 and
TD3, (2) recognition of K9me2 by an aromatic cage in TD3, and
(3) binding of G12 and G13 to a narrow groove between TD2 and
TD3. In agreement with this observation, peptide SPOT binding
experiments showed that alanine residues at the positions of G12
and G13 of H3 disrupted the interaction (Fig. 1e), indicating that
any bigger residue at this position would preclude peptide
binding. Moreover, E386 and R394 form a salt bridge inside TD3
and the backbone of G12–G13 is hydrogen-bonded to them
(Fig. 3c). Binding to modiﬁed histone peptide arrays showed that
mutation of E386 or R394 abolished the peptide-binding ability of
the Tudor domains (Supplementary Fig. 4a).
The K14ac is recognized by residues from TD2, TD3, and the
linker between them (Fig. 3d). The acetyl group forms two
hydrogen bonds with the backbone carbonyl-oxygen of G300 and
the backbone amine of Y389. The side chains of F332, F296,
A302, and Y389 form hydrophobic interactions with the acetyl-
lysine. Replacement of F332 by alanine caused a strong reduction
in afﬁnity of 3TD to the H3K9me2/K14ac peptide in peptide
array and ITC peptide-binding experiments (Figs. 1 and 2,
Supplementary Fig. 4a), and mutation of I388, which is a part of
the hydrophobic core of TD3, disrupted the binding completely
(Supplementary Fig. 4a), conﬁrming the importance of these
hydrophobic interactions. In addition, the backbone of the
histone peptide forms a series of hydrogen bonds with the
residues from TD3 further stabilizing the complex (Fig. 3c).
TD3 preferentially recognizes dimethylated K9. The
K9me2 side chain is inserted into an aromatic cage of TD3
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formed by W358, W363, and F379 (Fig. 3e). A direct hydrogen
bond between the carboxylate of D382 and the ε-ammonium of
K9me2 appears to further stabilize the complex explaining the
preference of this aromatic cage for binding of K9me2 over
K9me3. Disruption of the aromatic cage by mutation of W358 or
W363 abrogated H3K9me1 binding and reduced H3K9me2
peptide binding in peptide array binding (Fig. 1 and Supple-
mentary Fig. 4d) and ITC peptide-binding experiments (Fig. 2,
Supplementary Fig. 6c), while H3K9me3 binding was only 2-fold
reduced (see below). Similarly, mutation of D382 to alanine or
arginine mainly reduced binding of K9me1 to the pocket, but did
not affect the binding of K9me2 or K9me3 (Supplementary
Fig. 4d). This can be explained by the fact that K9me1 has the
weakest interactions with the aromatic cage, so that the D382-
mediated hydrogen bond is more critical for K9me1 than for
K9me2 binding (for K9me3 binding, also see below). Comparison
with the apo-structure of 3TD revealed a conformational change
associated with the methyl-lysine binding. In the absence of the
bound peptide, R384 is packed into the aromatic cage, blocking
the peptide-binding site (Fig. 3f). Consequently, alanine mutation
of R384 enhanced the peptide-binding afﬁnity of 3TD by 3- to 6-
fold (Fig. 2b, Supplementary Fig. 6b).
We also solved the structures of 3TD in complex with
H3K9me3/K14ac or H3K9me0/K14ac (Supplementary Fig. 3,
and Supplementary Table 1). In the H3K9me3/K14ac bound
structure, the H3 peptide interacts with 3TD in a similar mode as
in the H3K9me2/K14ac complex. The K9me3 is inserted into the
aromatic cage of TD3, and only slight rearrangements were
observed in the K9–aromatic cage interaction (Fig. 3g). In the
H3K9me0/K14ac complex structure, the unmethylated K9 and
residues preceding it cannot be tracked clearly suggesting that
they are disordered (Supplementary Fig. 3).
TD1 contains an inactive and incomplete aromatic cage.
Having shown that TD3 preferentially binds K9me2, we next
asked whether TD1 and TD2 also have potential roles in histone
binding. Sequence and structure alignments revealed that TD1
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Fig. 1 Peptide binding of SETDB1 Tudor domains. a Domain structure of SETDB1. b Modiﬁed histone peptide array binding of the 3TD and 3TD mutants.
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has an incomplete aromatic cage consisting of only H214 and
F234. The position of the ﬁrst aromatic residue is occupied by
K208, suggesting that TD1 is unable to bind methylated lysine
residues (Supplementary Fig. 2b and c). This was conﬁrmed by a
mutational study, as substitution of residues in TD1 did not or
only weakly affected peptide binding (Supplementary Fig. 4b).
TD2 preferentially recognizes trimethylated K9. TD2 has all
conserved aromatic residues (Y268, W275, Y277, F297, and
Y301), which are positioned proximal to the H3K9me/K14ac
peptides mentioned above. To test whether TD2 contributes to
peptide binding, we generated a Y268A mutant, which disrupts
the aromatic cage in TD2, and used it for both peptide array
binding and ITC peptide-binding assays. Interestingly, the Y268A
mutant showed a clear reduction in afﬁnity to the H3K9me3/
K14ac peptide, while the afﬁnities to H3K9me2/K14ac and
H3K9me1/K14ac peptides were not affected (Fig. 1b, c, and
Supplementary Fig. 4c). These data suggest that TD2 is involved
in H3K9me3/K14ac peptide binding.
In contrast, the mutation of W358 in TD3 (W358A), an
aromatic cage residue of TD3, led to a loss of H3K9me1/K14ac
binding and a strong reduction in binding of H3K9me2/K14ac,
while binding of H3K9me3/K14ac was only moderately reduced
in the peptide array binding (Fig. 1b, c). In the ITC peptide-
binding experiments, similar results were obtained; the afﬁnity to
H3K9me2/K14ac was reduced 18-fold and binding to H3K9me1/
K14ac was completely lost, but H3K9me3/K14ac binding was
reduced only mildly (2-fold) (Fig. 2 and Supplementary Fig. 6c).
These data suggest that TD3 is mainly involved in H3K9me1/2/
K14ac binding. The weaker binding of H3K9me1/2/K14ac to
W358A could be explained by the loss of the H-bond between the
W358 side chain and the carbonyl-oxygen of S10, leading to a
general reduction in peptide binding. We conclude that both TD2
and TD3 contribute to K9me binding, with TD2 showing
preference for H3K9me3 and TD3 preferring H3K9me1/2.
We further solved the structures of the W358A mutant in
complex with H3K9me3/K14ac or H3K9me2/K14ac peptides
(Fig. 4 and Supplementary Table 1). In the W358A H3K9me3/
K14ac structure, K9me3 indeed was bound to TD2, while the
peptide residues following S10 (including K14ac) adopted the
same conformation as in the wildtype structures (Fig. 4a–c). The
K9me3 was bound to an open aromatic cage in TD2 formed by
Y268, W275, and Y277, where W275 was rearranged compared to
the apo-structure to accept the trimethylated K9 (Fig. 4d, e). In
the W358A–H3K9me2/K14ac structure, electron density for the
K9me2 residue did not permit conﬁdent placement of the
dimethylated lysine, suggesting that it is partially disordered
(Supplementary Fig. 3). In summary, the Tudor domains of
SETDB1 collaborate to recognize the combinatorial histone
marks H3K9me/K14ac, with distinct Tudor domains showing
different methylation state selectivity.
SETDB1 is active on K14ac substrates on peptide arrays. To
investigate the peptide methylation activity of SETDB1, peptide
arrays were methylated by the N-terminal-deleted SETDB1 pro-
tein (190–1291) (Supplementary Fig. 7). The results showed that
SETDB1 methylates peptides containing K9 in un-, mono-, or
dimethylated forms, indicating that SETDB1 could methylate
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Fig. 2 3TD binding to different H3 peptides analyzed by ITC. a Representative ITC curves and dissociation constants of 3TD binding to different H3
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histone H3K9 up to trimethylation. SETDB1 activity was
observed on K14 acetylated and unacetylated substrates, and our
data revealed a strong inhibition of the SETDB1 activity by
phosphorylation of H3 peptides at S10 (as observed before9) or
T11 (not yet reported). Previously, methylation experiments with
peptides in solution showed that the K14ac modiﬁcation inhibits
the enzymatic activity of SETDB19. The discrepancy of these
results is possibly due to the different substrates used, because in
solution, the SET and 3TD domains would compete for binding
of substrate peptides, and acetylation of K14, which increases
3TD binding, would reduce catalytic activity. In contrast, in
peptide array methylation experiments, the substrate peptides are
present on the array at high density, and the binding of the 3TD
to one peptide in a spot would allow the SET domain to
methylate adjacent peptides in the same spot. Moreover, it cannot
be ruled out that the different enzyme sources in both studies
affected the results, because previously FLAG-tagged full-length
SETDB1 puriﬁed from HEK293 cells was used, whereas we used
an N-terminal-truncated SETDB1 puriﬁed from Sf9 cells. In the
peptide array methylation experiments, peptides containing
K14ac were methylated more strongly by SETDB1 (Supplemen-
tary Fig. 7), which would be in agreement with the recruitment of
this enzyme to these peptide spots via the 3TD domain. However,
given the limitations of the peptide array-based activity assay, this
result needs further validation.
H3 and nucleosomes binding of 3TD is K9me/K14ac depen-
dent. Having shown the speciﬁc binding of 3TD to H3 peptides
modiﬁed with K14ac and K9me, we next aimed to investigate the
role of H3 modiﬁcations in 3TD binding to native histones and
nucleosomes. Native histones puriﬁed from human HEK293 cells
and recombinant unmodiﬁed H3 were separated on SDS gels, and
the binding of 3TD to the blotted histone proteins was investi-
gated by far-western assays. As shown in Fig. 5a, 3TD speciﬁcally
binds to the native histone H3 (containing endogenous mod-
iﬁcations), but not to the unmodiﬁed recombinant H3. To
investigate the role of lysine acetylation in 3TD binding to H3, we
next used histones isolated from HEK293 cells treated with
HDAC inhibitors (trichostatin A or sodium butyrate). Histones
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were separated on SDS gels and their modiﬁcation state was
analyzed by western blot with anti-K9me and anti-K14ac anti-
bodies. As expected, H3 proteins isolated from cells treated with
HDAC inhibitors showed an increased H3K14ac signal, while the
content of K9 methylation did not change (Fig. 5b). Far-western
blots were conducted to study 3TD binding to both histone
preparations. Consistent with the gain in the H3K14ac level, an
increased 3TD binding was observed, conﬁrming that the 3TD
binding to native histones is conferred by histone acetylation.
Next, we used the GST-tagged 3TD to pull-down mononucleo-
somes in chromatin domain immunoprecipitation (CIDOP)
experiments29,30. Wildtype 3TD, but not the F332A mutant (with
disrupted acetyl-lysine binding pocket), was able to pull-down H3
containing K14ac and K9me2 (Fig. 5c). H3K4me3 was analyzed
as unrelated active mark and found not to be enriched in the pull-
down. The pull-down was analyzed by mass spectrometry and
showed strong enrichment of doubly modiﬁed H3K9me/K14ac
peptides (1.5 to 2-fold for K9me1/K14ac and K9me3/K14ac, up to
4-fold for K9me2/K14ac) (Fig. 5d and Supplementary Fig. 8). The
identity of the K9me2–K14ac peptide was conﬁrmed by MS/MS
(Fig. 5e). Unmodiﬁed H3 (9–17) and unrelated peptides detected
by mass spectrometry analysis were depleted or not enriched
conﬁrming the speciﬁcity of the pull-down reaction (Supple-
mentary Fig. 8).
SETDB1 co-localizes with H3K14ac/K9me3 chromatin. Next,
we analyzed available ChIP-seq datasets from mESC cells for
SETDB131, H3K9me332, and H3K14ac33 to investigate the in vivo
genome binding of SETDB1. As shown in Fig. 6a, we observed co-
occurrence of these signals at many sites. Peak calling and
analysis of the overlap of peaks and peak regions conﬁrmed a
strong enrichment of SETDB1 at H3K9me3 peaks (Fig. 6b),
which is in agreement with the literature ﬁndings31,32. This
correlation was expected, because H3K9me3 is the methylation
product of SETDB1. However, we also found that 14% of all
SETDB1 peaks overlap with H3K14ac peaks and 28% of all
H3K14ac peaks overlap with H3K9me3 peaks (Fig. 6b). Strik-
ingly, we observed that 9.7% of all SETDB1 peaks (2231) overlap
with H3K9me3 and H3K14ac peaks, which is a strong enrich-
ment, because only 3.9% were expected by chance (=28% of 14%).
Further evaluation of the signiﬁcance of all binary and ternary
overlaps was performed by Fisher’s exact test, considering the size
and number of regions in the data sets. This resulted in highly
signiﬁcant two-sided p-values in all cases (always p< 1E-300). In
addition, the high signiﬁcance of the overlap of H3K14ac peaks
with the intersection of SETDB1 and H3K9me3 peaks was con-
ﬁrmed by randomization of the H3K14ac regions (Supplementary
Note 2).
Clustering of the data on SETDB1 peaks showed that
H3K9me3 signals were enriched at or near the vast majority of
the SETDB1 binding sites (Fig. 6c, clusters 1–7), and two clusters
showed co-occurrence of SETDB1 and H3K9me3 with H3K14ac:
cluster 6 (strongly) and cluster 7 (weakly). Cluster 6 contains
12.2% of all SETDB1 peaks, which is in line with the analysis
presented above. We conclude that K14ac is present at a subset of
SETDB1 binding sites. Prompted by the documented function of
SETDB1 to introduce H3K9 methylation at repeats, we analyzed
the overlap of the SETDB1 peaks in the different clusters with
repeats (Fig. 6d). We observed an enrichment of LTRs in clusters
2–4 (strongly), 7 and 8 (moderately). Moreover, cluster 6,
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containing regions with SETDB1, H3K9me3, and H3K14ac
signals, showed a very strong enrichment of LINE elements.
We conclude that a subset of SETDB1 binding sites contains the
H3K9me3/H3K14ac double modiﬁcation and these sites are
enriched in LINE elements. Next, we calculated meta-proﬁles of
SETDB1 read density using LTR and LINE elements overlapping
with SETDB1 peaks (Fig. 6e). These proﬁles clearly show that the
binding of SETDB1 to LTRs and LINEs differs. While SETDB1
binds to LTRs in the center of the elements, LINEs are bound at
the edges. Further analyses showed that H3K9me3 density
mirrors SETDB1 density on repeat elements overlapping with
SETDB1 peaks (Supplementary Fig. 9a). On LINE elements, a
weak H3K14ac signal was detected as well, which (similar to the
SETDB1 signal) was centered at the edges of the LINE elements.
In agreement with our analysis, the H3K14ac signal was strongly
increased on LINE elements from cluster 6 (Supplementary
Fig. 9b). The clear H3K14ac enrichment at the ﬂanks of SETDB1
overlapping LINE elements (in particular from cluster 6) strongly
supports our conclusion that H3K14ac is involved in the targeting
of SETDB1.
Sub-nuclear localization of 3TD-binding pocket mutants.
Finally, we investigated if the sub-nuclear localization of 3TD in
mouse NIH3T3 cells depends on its H3 tail interaction (Fig. 7 and
Supplementary Figs. 10 and 11). 3TD and 3TD mutants were
expressed as fusion constructs with mCerulean or mVenus in
mouse NIH3T3 cells. Wildtype 3TD showed a granular dis-
tribution with perinucleolar enrichment. As expected, co-
expression of two wildtype constructs resulted in a perfect over-
lay of the two ﬂuorescence signals. In contrast, all mutants
showed clear differences in their sub-nuclear localization. F332A
displayed a diffused localization with enrichment in nucleoli,
while I388A and R394A showed diffused localization with
nucleolar exclusion. These data show that substitutions of single
residues important for peptide binding (F332, I388, or R394)
changed the sub-nuclear localization of the mutants, indicating
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that H3 tail binding affects the sub-nuclear localization of 3TD.
We also investigated the contribution of 3TD to the localization
of the full-length SETDB1, but quick and efﬁcient export of
SETDB1 from the nucleus, consistent with previous reports34,35,
prevented us from drawing any conclusions.
Discussion
It is well established that epigenetic writers frequently also con-
tain reading functions36. Often the modiﬁcation introduced by
the writer is read by the reader, as exempliﬁed in the cases of the
SUV39H137 and G9a H3K9 PKMTs38, a process that can con-
tribute to propagation and spreading of the mark and by doing so
to ensure stability of the epigenome network. However, under
speciﬁc conditions, efﬁcient switching mechanisms are required
to change functional chromatin states. Under these circum-
stances, recruitment of the required writers would depend on the
reading of an “opposing” signal, as discovered in this work for the
SETDB1 H3K9 trimethylase. We show here that the 3TD domain
of SETDB1 speciﬁcally binds to histone H3 tails containing a
combinatorial modiﬁcation at K9 and K14. The activating mod-
iﬁcation, H3K14ac, is recognized as a primary mark responsible
for binding, and must be accompanied by methylation of H3K9,
which is associated with active or repressed chromatin depending
on the methylation state. Co-occurrence of K9 methylation and
K14 acetylation had been shown previously by mass spectrometry
in histone H3 isolated from different human cell types (Supple-
mentary Fig. 12)39,40, but the functions of these double marks are
not known. We show activity of SETDB1 on H3K14-acetylated
substrates in peptide array methylation experiments, suggesting
that recruitment of SETDB1 to H3K9me/K14ac chromatin can
result in silencing of the target regions, by introduction of
H3K9me3 via the SET domain of SETDB1 and by deacetylation
of K14ac via SETDB1-associated HDAC activity. This ﬁnding is
in agreement with the observation that H3K9me3 levels decrease
on H3 tails with acetylated K14 after the combined knock-down
of the three H3K9 methyltransferases EHMT1, EHMT2, and
SETDB140, and suggests that SETDB1 is responsible for this
effect.
The three Tudor modules of SETDB1 fold as a tightly con-
nected protein domain. Binding of K14ac occurs at the interface
between TD2 and TD3 and is mediated by hydrogen bonding and
hydrophobic interactions. Previously, the bromodomain has been
characterized as an acetyl-lysine binding module41, and tandem
PHD ﬁngers of DPF3b42 and MOZ43–45 have also been reported
to recognize H3K14ac. The MOZ tandem PHD ﬁnger in addition
interacts with acylated lysine46. Moreover, the YEATS domains of
AF9 and Taf14 were reported to recognize H3K9ac47,48 as well as
lysine crotonylation49,50. In contrast, Tudor domains have been
identiﬁed as methyl-lysine or methyl-arginine reading
domains26,27. Our biochemical and structural analyses demon-
strate that 3TD of SETDB1 functions as a recognition domain for
acetyl-lysine (Fig. 8). Previously, binding to a similar bivalent
H3K9me3/H3K18ac modiﬁcation has been observed for
TRIM3351. However, in that case the binding is mediated by two
separate reading domains (one PHD domain and one bromo-
domain), which need to reside in a greater distance to one
another to allow for speciﬁc binding of H3K9me3/H3K18ac to
happen. The observation that TRIM33 binding to H3K9me3/
H3K18ac activates gene expression, while SETDB1 binding to
H3K9me/K14ac likely leads to gene silencing (because H3K9me3
is introduced and K14ac could be removed), suggests that these
combinatorial K9me/Kac modiﬁcation states have distinct roles.
Interestingly, the conformation of the peptide bound to 3TD
depends on the modiﬁcation state of K9. While K9me3 binding
occurs at the TD2 domain with higher afﬁnity, TD3 preferentially
recognizes K9me1 and K9me2 substrates—illustrating a pocket
switch mechanism in a histone reading domain. It is conceivable
that this conformational change of the bound peptide triggers
downstream effects in SETDB1, for example allosterically mod-
ulating its activity or controlling the interaction with its complex
partners, like KAP-19, the NuRD complex19–21, DNMT3A17,
other H3K9 PKMTs18, or the HUSH complex16. Future work will
be needed to explore these effects in more detail.
Our data suggest that H3K9me and K14ac deﬁne a bivalent
chromatin state, which is bound by 3TD of SETDB1, in agree-
ment with other examples documenting roles of SETDB1 at
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bivalent chromatin32,52. By this process, SETDB1-mediated
silencing of endogenous retroviral elements might be connected
to the activating H3K14ac modiﬁcation, when it co-occurs with
methylated H3K9. After recruitment of SETDB1 to H3K9me1/
K14ac or H3K9me2/K14ac sites, SETDB1 is expected to methy-
late them to the K9me3 state (Fig. 8b), which is in agreement with
the binding of SETDB1 at LINE elements containing K9me3/
K14ac. Depending on the exact composition of the SETDB1
complex bound, deacetylation of K14ac could also be catalyzed,
suggesting that SETDB1 bound to K9me3 marked LTRs initially
could have been recruited by K14ac, but this modiﬁcation has
already been removed. Recruitment by K14ac might help to focus
SETDB1 activity on the most active LTR and LINE elements,
supporting the silencing of active and hence most dangerous
repeat elements. In agreement with this model, the SETDB1-
mediated silencing of endogenous retroviral elements has been
also linked to histone variant H3.3, which is another signal often
associated with gene activation53. Hence, the SETDB1 silencing
system might be speciﬁcally attracted to repeat elements deco-
rated with activating marks, such as H3.3 and H3K14ac. In
summary, our data suggest that recruitment of SETDB1 to
H3K9me/H3K14ac might allow to efﬁciently counteract acetyla-
tion of these elements, introduce K9 trimethylation, and ensure
silencing of retrotransposons containing internal activating ele-
ments. Future work may include the generation of endogenous
SETDB1 mutants containing amino acid exchanges in 3TD by
CRISPR/Cas9-mediated homologous recombination and sub-
sequent studies of the biological consequences of these exchanges.
Methods
Protein expression and puriﬁcation. Wildtype SETDB1–3TD was cloned into the
pET28a-MHL (residues 190–410), pGEX6P2, and pGEX-4T-1 (residues 197–403)
vectors. Point mutants were generated by site-directed mutagenesis. Wildtype and
mutant proteins were expressed in an SGC-generated derivative strain of BL21
Escherichia coli with the pRARE plasmid for overcoming the codon bias. Cells were
grown in TB medium or in M9 minimal medium supplemented with 15NH4Cl for
the NMR analyses. Expression was induced with 0.5 mM IPTG, and the bacteria
were harvested by centrifugation and lysed by sonication. The GST-fusion proteins
were puriﬁed using Glutathione-Sepharose 4B beads (GE Healthcare). The GST-tag
was either cleaved with PreScission protease, or left for the purposes of western blot
analysis or peptide array probing, in which case the GST-fusion protein was eluted
off the Glutathione-Sepharose beads using 50 mM reduced L-glutathione (Sigma-
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Aldrich). The 6×His-tagged protein was puriﬁed by an Ni-NTA column (Qiagen)
followed by a gel ﬁltration column (Superdex 75, GE Healthcare). For SETDB1
methylation kinetics, an N-terminus-deleted construct was cloned into the
pFBOH-SUMOstar-TEV vector as 6×His-SUMO-TEV-SETDB1 (190–1291) fusion
protein. The resulting virus was transformed into Sf9 insect cell for protein
expression, and puriﬁed using Ni-NTA column (Qiagen) followed by ion exchange
chromatography (Hitrap Q HP column).
CD spectroscopy. Folding of puriﬁed proteins was analyzed by circular dichroism
(CD) spectroscopy. CD measurements were performed using a J-815 circular
dichroism spectrophotometer (JASCO Corporation, Tokyo, Japan) using GST-
tagged 3TD domains in 100 mM KCl, 5 mM HEPES pH 7.5, and 5% glycerol.
Depending on the protein preparation, spectra were measured at 10 µM or 2 µM
protein. The spectra were collected at 22 °C using a 0.1-mm cuvette in a wavelength
range between 195 and 240 nm. For each sample, at least 60 scans were collected
and averaged.
Protein crystallization. Puriﬁed proteins mixed with a 3- to 5-fold stoichiometric
excess of the respective peptides were crystallized using the sitting drop vapor
diffusion method at 18 °C by mixing 0.5 µl of the protein with 0.5 µl of the reservoir
solution. The 3TD bound with H3K9me2/K14ac or H3K9me3/K14ac complex was
crystallized in 25% PEG 3350, 0.2 M NaCl, 0.1 M Hepes pH 7.5, and 5% glycerol.
The 3TD–H3K9me0/K14ac complex was crystallized in 20% PEG 5000 mono-
methyl ether, 0.1 M Bis-Tris pH 6.5. The 3TD W358A mutant bound with
H3K9me2/K14ac or H3K9me3/K14ac complex was crystallized in 25% PEG 3350,
0.2 M Li2SO4, and 0.1 M Hepes pH 7.5. Further details of crystallization and
structure determination are given in Supplementary Note 1.
Nuclear magnetic resonance spectroscopy. NMR experiments were collected on
a Bruker Avance 500-MHz spectrometer equipped with a cryogenic probe. Che-
mical shift perturbation experiments were carried out using uniformly 15N-labeled
wildtype 3TD protein in 20 mM Tris/HCl pH 7.0 and 150 mM NaCl. 1H, 15N
HSQC spectra were recorded at 25 °C in the presence of increasing concentrations
of histone tail peptides. Kd values were calculated by a nonlinear least-squares
analysis in Kaleidagraph using the equation
Δδ ¼ Δδmax cL þ cP þ Kdð Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
cL þ cP þ Kdð Þ24cLcP
q
 
=2cP;
where cL is the concentration of the peptide, cP is the concentration of the protein,
Δδ is the observed normalized chemical shift change, and Δδmax is the normalized
chemical shift change at saturation, calculated as
Δδ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ΔδHð Þ2þ ΔδN=5ð Þ2
q
;
where δ is the chemical shift in p.p.m.
Isothermal titration calorimetry. ITC experiments were carried out at 25 °C on a
VP-ITC calorimeter (MicroCal). Protein and peptide were kept in an identical
buffer of 20 mM Tris/HCl pH 7.0 and 150 mM NaCl. ITC measurements were
carried out with protein and ligand concentrations ranging from 50 to 100 μM and
1–2 mM, respectively. Binding isotherms were analyzed by nonlinear least-squares
ﬁtting of the data using Microcal ORIGIN software (Microcal) using a one-site
binding model.
Mass spectrometry. 3TD pull-down and input control mononucleosomal chro-
matin isolated from HEK293 cells were resolved on 15% SDS-PAGE gels. The
bands corresponding to histone H3 were excised from the gels and shredded into
small 1-mm cubes. Coomassie, detergents, and other chemicals that could interfere
with trypsin digestion or MALDI analysis were removed in three subsequent 15-
min incubation steps with 100 µl of 1:1 (v/v) mixture of 50 mM ammonium
bicarbonate and acetonitrile. After each incubation, the gel pieces were dehydrated
by addition of 100 µl pure acetonitrile and the liquid was discarded after each wash.
For in-gel digestion, the gel pieces were rehydrated in 50 µl 25 mM ammonium
bicarbonate containing 5 ng/µl sequencing-grade modiﬁed trypsin (Promega) and
incubated at 37 °C for 30 min. Afterward, the supernatant containing the digested
peptides was transferred into a new tube, ﬂash frozen in liquid nitrogen for later
use, or directly spotted on an AnchorChip (Bruker) target plate, dried, and covered
with alpha-cyano-4-hydroxycinnamic acid (HCCA). Peptide mass ﬁngerprinting
was done on an AutoFlex Speed MALDI TOF/TOF mass spectrometer (Bruker)
operated in reﬂected positive mode. The spectra were recorded between 500 and
4000 m/z. Peptide calibration standard (Bruker) was used for mass calibration. The
obtained spectra were analyzed with the BioTools package (Bruker). For MS/MS
analysis, selected peaks were fragmented and measured in LIFT mode, the mass
spectra were matched against possible peptides found in nonredundant (nr)
database using MASCOT software, or matched to the theoretical sequence of the
peptide identiﬁed in the ﬁrst PMF analysis.
Cell lines. Human HEK293 and mouse NIH3T3 cells were obtained from the
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures.
The mouse ES cell line E14 (129/Ola) was obtained from Wolf Reik (Cambridge,
UK). All cells were free of mycoplasma.
Binding and methylation of peptide arrays. Experiments to determine the
binding speciﬁcity of 3TD wildtype and mutants were performed using CelluSpots
peptide arrays (MODiﬁed Histone Peptide Array, Active Motif), as described
previously, in 20 mM HEPES pH 7.5, 100 mM KCl, 1 mM EDTA, 0.2 mM DTT,
and 10% glycerol54. All peptide array binding studies were conducted at least in
two technical repeats. Annotations of all spots are given in Supplementary Table 2.
The amounts of GST-fused Tudor proteins used in peptide array binding and
western blot analyses ranged from 0.5 to 100 nM. For methylation analysis,
MODiﬁed Histone Peptide arrays (Active Motif) were incubated with 20 nM
SETDB1 in buffer (50 mM Tris/HCl pH 9.0, 4 mM DTT, 5 mM MgCl2) supple-
mented with 0.38 µM radioactively labeled [methyl-3H]-AdoMet (Perkin Elmer)
for 2 h at room temperature. The arrays were then washed 5 times with wash buffer
(100 mM NH4HCO3 and 1% SDS), incubated in Amplify NAMP100 (GE
Healthcare) for 5 min, and then exposed to Hyperﬁlm TM ECL high-performance
chemiluminescence ﬁlm (GE Healthcare) in the dark at −80 °C for 1–7 days.
Binding to histones and histone tails. Native histones were isolated by acid
extraction55 from HEK293 cells, and recombinant histone H3 was purchased from
New England Biolabs. For the experiment with HDAC inhibitors, cells were treated
for 48 h with 0.4 mM TSA or 5 mM sodium butyrate. Five micrograms of native
histones and matching amount of recombinant H3 were electrophoresed on 18%
SDS-PAGE and transferred onto nitrocellulose membranes. The membrane was
then blocked in 5% milk in TBST and incubated with puriﬁed GST-tagged 3TD,
followed by the anti-GST (GE Healtcare 27457701A, dilution 1:5000) and anti-goat
antibody (Sigma A4174, dilution 1:10000). The amount of GST-fused Tudor
protein used in western blot analyses was 100 nM. All experiments were performed
in duplicates or triplicates. In the western blots, following antibodies were used:
anti-K14ac (Millipore MABE351, dilution for checking speciﬁcity: 1:2000 or
1:1000; for western blot: 1:500), anti-H3K9me3 (Abcam ab8898, dilution 1:2000),
anti-H3K9me2 (Abcam ab1220, dilution 1:1000), and anti-H3K4me3 (Abcam
ab8580, dilution 1:2000). For speciﬁcity analysis of antibodies, see Supplementary
Fig. 13. Secondary antibodies were anti-rabbit IgG HRP (GE Healtcare NA934,
dilution 1:5000) and anti-mouse IgG HRP (GE Healtcare NXA931, dilution
1:5000). Native histone and nucleosome pull-down experiments were done at least
in two biological repeats. All antibodies were used following the manufacturer’s
recommendations. Uncropped gel images are shown in Supplementary Fig. 14.
Analysis of SETDB1 genomic binding. SETDB1, H3K9me3, and K14ac ChIP data
from murine embryonic stem cells were from GSE1764231, GSE1837132, and
GSE3128433, respectively. The raw reads were mapped to mm10 with Bowtie2,
using default settings56 and RPKM normalized. Peaks were called with MACS57 in
the Galaxy environment58. The quantitative analyses of peak overlap were carried
out in Galaxy using the Intersect tools. ComputeMatrix and PlotHeatmap in
DeepTools was used for generation of heatmaps, meta-proﬁles, and K-means
clustering59. Statistics were determined using the Fisherʼs Test and ShufﬂeBED
tools in DeepTools. Overlap regions were checked not to include blacklisted
regions for mm10 downloaded from ENCODE. LINE and LTR elements were
downloaded from NCBI table browser. The Integrative Genomics Viewer was used
for visualization of the data and preparation of browser shots60. For annotation of
repeats and known chromatin modiﬁcations to genomic regions, EpiExplorer was
used61.
Fluorescence microscopy. For sub-nuclear localization studies, SETDB1 3TD
wildtype and mutant domains were cloned in expression constructs containing an
NLS and fused to mCerulean and mVenus. NIH3T3 cells were seeded on tissue
culture dishes with glass bottom and 1 day later co-transfected with plasmids
expressing one mCerulean and one mVenus tagged 3TD wildtype or mutant
domain using FuGENE HD (Promega) according to the manufacturerʼs instruc-
tions. After 24 h, images were collected using a Zeiss LSM 710 confocal microscope
and Plan-Apochromat 63×/1.40 Oil DIC M27 objective.
Data availability. Structural data have been submitted to the PDB database under
accession numbers 6BHD, 6BHE, 6BHG, 6BHH, and 6BHI. All other data sup-
porting the ﬁndings of this study are available within the paper and its supple-
mentary information ﬁles. Additional primary data are available from the
corresponding authors upon reasonable request.
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